Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Hypothesis: Extra-hepatic acromegaly: a new paradigm?

Neggers SJ, Kopchick JJ, Jørgensen JO, van der Lely AJ.

Eur J Endocrinol. 2011 Jan;164(1):11-6. doi: 10.1530/EJE-10-0969. Epub 2010 Nov 2.

2.

Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.

Franck SE, van der Lely AJ, Delhanty PJ, Jørgensen JO, Neggers SJ.

Eur J Endocrinol. 2015 Nov;173(5):553-61. doi: 10.1530/EJE-15-0519. Epub 2015 Aug 4.

PMID:
26243033
3.

Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.

Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G.

Neuro Endocrinol Lett. 2008 Aug;29(4):571-6.

PMID:
18766168
4.

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone.

van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, Neggers S, Birman P.

Eur J Endocrinol. 2011 Mar;164(3):325-33. doi: 10.1530/EJE-10-0867. Epub 2010 Dec 10.

5.

Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.

Marazuela M, Lucas T, Alvarez-Escolá C, Puig-Domingo M, de la Torre NG, de Miguel-Novoa P, Duran-Hervada A, Manzanares R, Luque-Ramírez M, Halperin I, Casanueva FF, Bernabeu I.

Eur J Endocrinol. 2009 Apr;160(4):535-42. doi: 10.1530/EJE-08-0705. Epub 2009 Jan 15.

6.

Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery.

Rubeck KZ, Madsen M, Andreasen CM, Fisker S, Frystyk J, Jørgensen JO.

Eur J Endocrinol. 2010 Nov;163(5):717-26. doi: 10.1530/EJE-10-0640. Epub 2010 Sep 2.

7.

What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?

Muhammad A, van der Lely AJ, O'Connor RD, Delhanty PJ, Dal J, Dallenga AH, Feelders RA, Janssen JA, Jorgensen JO, Neggers SJ.

Eur J Endocrinol. 2016 May;174(5):663-7. doi: 10.1530/EJE-15-1150. Epub 2016 Feb 22.

PMID:
26903550
8.

Growth hormone receptor antagonists.

van der Lely AJ, Kopchick JJ.

Neuroendocrinology. 2006;83(3-4):264-8. Epub 2006 Oct 13. Review.

PMID:
17047392
9.

Acromegaly: a new therapy.

Friend KE.

Cancer Control. 2002 May-Jun;9(3):232-5. Review.

10.

Somatostatin analog and pegvisomant combination therapy for acromegaly.

Neggers SJ, van der Lely AJ.

Nat Rev Endocrinol. 2009 Oct;5(10):546-52. doi: 10.1038/nrendo.2009.175. Review.

PMID:
19763127
11.

Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.

Neggers SJ, Franck SE, de Rooij FW, Dallenga AH, Poublon RM, Feelders RA, Janssen JA, Buchfelder M, Hofland LJ, Jørgensen JO, van der Lely AJ.

J Clin Endocrinol Metab. 2014 Oct;99(10):3644-52. doi: 10.1210/jc.2014-2032. Epub 2014 Jun 17.

PMID:
24937542
12.

Clinical use of pegvisomant for the treatment of acromegaly.

Drake WM, Trainer PJ.

Treat Endocrinol. 2003;2(6):369-74. Review.

PMID:
15981941
13.
14.

Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.

Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G.

Eur J Endocrinol. 2006 Mar;154(3):467-77.

15.

Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.

Brue T, Castinetti F, Lundgren F, Koltowska-Häggström M, Petrossians P; ACROSTUDY investigators.

Eur J Endocrinol. 2009 Nov;161 Suppl 1:S11-7. doi: 10.1530/EJE-09-0333. Epub 2009 Aug 14.

16.

The German ACROSTUDY: past and present.

Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Strasburger CJ; German Pegvisomant Observational Study.

Eur J Endocrinol. 2009 Nov;161 Suppl 1:S3-S10. doi: 10.1530/EJE-09-0350. Epub 2009 Aug 14.

17.

Management of endocrine disease: GH excess: diagnosis and medical therapy.

Andersen M.

Eur J Endocrinol. 2013 Nov 29;170(1):R31-41. doi: 10.1530/EJE-13-0532. Print 2014 Jan. Review.

18.

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.

Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ.

Eur J Endocrinol. 2009 Apr;160(4):529-33. doi: 10.1530/EJE-08-0843. Epub 2009 Jan 13.

19.

New perspectives in the medical treatment of acromegaly.

Colao A, Pivonello R, Auriemma RS, Galdiero M, Guerra E, Milone F, De Leo M, Lombardi G.

J Endocrinol Invest. 2005;28(11 Suppl International):58-66. Review.

PMID:
16625847
20.

Pegvisomant: an advance in clinical efficacy in acromegaly.

Stewart PM.

Eur J Endocrinol. 2003 Apr;148 Suppl 2:S27-32. Review.

Items per page

Supplemental Content

Write to the Help Desk